Who is sponsoring NCT05370482?

NCT05370482 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT05370482?

Interventions in NCT05370482: Focal laser ablation.

What condition does NCT05370482 study?

NCT05370482 studies Prostate Neoplams, Magnetic Resonance Imaging, Laser Ablation.

Is NCT05370482 still recruiting?

NCT05370482 is currently status unknown. Last updated 26 October 2022.

Last reviewed 2022-10-26 · How we verify

NCT05370482

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MRI-guided Focal Laser Ablation Prostate Cancer

Status unknown NA Last updated 26 October 2022

What this trial tests

NA trial testing Focal laser ablation in Prostate Neoplams, Magnetic Resonance Imaging, Laser Ablation in 10 participants. Status unknown.

Timeline

11 April 2022

Primary endpoint
11 October 2023

11 April 2025

Quick facts

Lead sponsor	Radboud University Medical Center
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	11 April 2022
Primary completion	11 October 2023
Estimated completion	11 April 2025
Sites	1 location across Netherlands

Drugs / interventions tested

Focal laser ablation

Conditions studied

Prostate Neoplams, Magnetic Resonance Imaging, Laser Ablation — all drugs for Prostate Neoplams, Magnetic Resonance Imaging, Laser Ablation →

Sponsor

Radboud University Medical Center

Who can join

Adults 45 to 76, male only, with Prostate Neoplams, Magnetic Resonance Imaging, Laser Ablation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prostate cancer is the most frequent malignancy in the male population of developed countries and has a substantial socio-economic impact. Focal therapies, including focal laser ablation (FLA), are gaining ground as a novel strategy to treat organ-confined low- to intermediate risk PCa while preserving healthy tissue and reduce treatment-related morbidity associated with radical treatments. This project has the goal to perform a feasibility study on magnetic resonance imaging (MRI)-guided focal laser ablation using the TRANBERG®\|Thermoguide Therapy System including TRANBERG®Thermoguide Workstation for MR thermometry developed by the company CLS AB.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Focal ablation therapy presents promising results for selectively localized prostate cancer patients.
Feng D, Li D, Xiao Y, Wu R, et al · · 2023 · cited 22× · PMID 37691892 · DOI 10.21147/j.issn.1000-9604.2023.04.08

Verify or expand the search:

Other trials of Focal laser ablation

Trials testing the same drug.

NCT06916013 — Focal Laser Ablation in Prostate Cancer · not yet recruiting
NCT04379362 — MRI-guided Focal Laser Ablation · Phase 2 · unknown

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05370482 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 26 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05370482.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing